Skip to main content

Table 1 Demographic and baseline clinical characteristics

From: Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

Characteristic Value
Age (median, range) 54.1 (34.5–77.4)
Tumor subtype
 Hormone-positive 16 (64%)
 TNBC 9 (36%)
Histology
 Ductal 18 (72%)
 Lobular 4 (16%)
 Other 3 (12%)
Time (months) from diagnosis of metastatic disease (median, range) 18.1 (2–116)
Time (months) receiving bevacizumab before registration (median, range) 8.4 (1.6–24.7)
Number of previous treatment lines for metastatic disease
 1 3 (12%)
 2 9 (36%)
 3 3 (12%)
 4 7 (28%)
 5 2 (8%)
 7 1 (4%)
Companion drug in the pre-trial regimen:
 Capecitabine 13 (52%)
 Paclitaxel 10 (40%)
 Docetaxel 1 (4%)
 Cisplatin 1 (4%)
ECOG 0 15 (60%
ECOG 1 10 (40%)
PD-L1 expression:
 Positive (> 1%) 4 (16%)
 Negative (0%) 16 (64%)
 Unknown 5 (20%)